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Pancreatic cancer (PC) is one of the leading causes of mortality rate globally and is usually 
associated with obstructive jaundice (OJ). Up to date, there is no clear consensus on whether biliary 
decompression should be performed prior to surgery and how high levels of serum bile affects the 
outcome of PC. Therefore, our study aims were to characterise the effect of bile acids (BAs) on 
carcinogenic processes using pancreatic ductal adenocarcinoma (PDAC) cell lines and to investigate 
the underlying mechanisms. Liquid chromatography-mass spectrometry was used to determine 
the serum concentrations of BAs. The effects of BAs on tumour progression were investigated 
using different assays. Mucin expressions were studied in normal and PDAC cell lines and in human 
samples at gene and protein levels and results were validated with gene silencing. The levels of BAs 
were significantly higher in the PDAC + OJ group compared to the healthy control. Treating PDAC 
cells with different BAs or with human serum obtained from PDAC + OJ patients enhanced the rate 
of proliferation, migration, adhesion, colony forming, and the expression of MUC4. In PDAC + OJ 
patients, MUC4 expression was higher and the 4-year survival rate was lower compare to PDAC 
patients. Silencing of MUC4 decreased BAs-induced carcinogenic processes in PDAC cells. Our results 
show that BAs promote carcinogenic process in PDAC cells, in which the increased expression of MUC4 
plays an important role. Based on these results, we assume that in PC patients, where the disease is 
associated with OJ, the early treatment of biliary obstruction improves life expectancy.
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PC  Pancreatic cancer
PDAC  Pancreatic ductal adenocarcinoma
TCA  Taurocholic acid
TCDCA  Taurochenodeoxycholic acid
TDCA  Taurodeoxycholic acid
TSBA  Total serum bile acid
Pancreatic cancer (PC) is associated with extremely poor survival and high mortality rate. Currently, PC is the 
seventh leading cause of cancer-related deaths  worldwide1. One of the most common reasons for the poor clinical 
outcome is the lack of specific symptoms; as a result, approximately 80% of patients are diagnosed at an advanced 
stage, when most of them are  inoperable2–5. The most common form of PC is pancreatic ductal adenocarcinoma 
(PDAC), which is responsible for approximately 90% of  cases6. Most of the PDAC arises from ductal cells in the 
head of the pancreas. As tumour grows, it prevents the flow of bile and, as a result, obstructive jaundice (OJ) 
develops. Elevated serum levels of bile acids (BAs) influence the function of several organs; they have also proved 
to have tumorigenic potential in both gastrointestinal and breast  cancer7. Although surgical intervention is widely 
regarded as the most effective way for the treatment of  PC3,8, the use of preoperative biliary stenting is often the 
basis for debate and it usually takes time to make a  decision9–11. Moreover, there is no consensus regarding the 
role of BAs in the initiation and progression of  PC12. Some studies indicate that BAs inhibit the proliferation of 
PC cells due to their cytotoxic  properties13,14, while others found that BAs promote tumour development and 
progression by increasing the expression of COX-2 or  mucins15–17.
In recent years, considerable attention has been paid to the diagnostic use of mucins in PC. Twenty-one mucin 
genes have been identified in humans and, among them, MUC1, -4 and -5AC proved to be potential biomarkers 
to assess the progression of PC. These genes are mainly overexpressed in PC, play role in tumour cell growth 
and associate with a poor outcome for PC  patients16,18–20. Several studies indicate that BAs play an extensive role 
in tumour progression by altering the expression of  mucins17,21–25. In the oesophagus, BAs upregulate mucin 
expression, in which phosphatidylinositol 3-kinase and nuclear factor-κB (NK-κB) signalling pathways play a 
 role17,23,24. The role of NK-κB in bile-induced mucin expression has also been implicated in gastric epithelial 
 cells25. In contrast, there has not been in-depth study pertaining to the pancreas; thus, this study aims (i) to 
investigate how BAs treatment affect the behaviour of PDCA cells and ii) to identify the mechanisms that medi-
ate the effects of BAs.
We have shown that BAs increase the tumorigenic potential of PDAC cells, through the overexpression of 
MUC4. In addition, we investigated the expression of MUC4 in human PC samples and identified a relation 
between the presence of OJ and increased expression of MUC4. Moreover, we have found that the 4-year overall 
survival rate of the PDAC + OJ patients was significantly poorer than that of the PDAC patients. Taken together 
our results show that bile accelerates carcinogenic processes, which can be of great importance in the therapy 
of PC.
Materials and methods
Ethical aspects. The clinical part of the study was carried out with the approval of the Ethics Committee 
of the University of Szeged (No.: 4714), followed by the EU Member States’ Directive 2004/23/EC on presumed 
consent practice for tissue collection, the guidelines of the Helsinki Declaration and GDRP. Written informed 
consent was obtained from all patients and healthy volunteers for sample and data collection.
Pathological characterisation of the patients. Serum levels of BAs were investigated in PDAC patients 
with OJ (average age: 72.6 ± 9.8; male/female ratio: 5/5) or without OJ (average age: 80 ± 2.5; male/female ratio: 
2/3) and in healthy volunteers (average age: 40.9 ± 18.77; male/female ratio: 6/8). In all groups, BAs were identi-
fied in fasting serum samples. See Table 1 for the details of patients.
We performed immunohistochemistry on pancreatic samples obtained from 65 patients. These patients 
have been classified into the following groups: (1) PDAC (average age: 65.6 ± 1.4; male/female ratio: 17/8), (2) 
PDAC + OJ (average age: 66.4 ± 1.7; male/female ratio: 13/12), (3) neuroendocrine tumour (NE) (average age: 
68.1 ± 2.25; male/female ratio: 8/3) and (4) control group (average age: 62.75 ± 3.3; male/female ratio: 1/3). All 
the samples were obtained from surgical resection or biopsy. Pathological characterisation of the PDAC tumours, 
including PDAC + OJ tumours, confirmed that most of them were moderately differentiated (grade 2, n = 30); 14 
tumours were poorly differentiated (grade 3), whereas 6 tumours were well-differentiated (grade 1). The majority 
of PDAC developed in the head. Among the PDAC patients, 22 were in stage IV, 22 in stage III and 6 in stage II. 
Metastasis was present in 25 cases. We followed up on all patients for 48 months, during which time all PDAC 
and PDAC + OJ patients died. See Table 2 for the details of patients.
Chemicals and solutions. TaqMan gene expression assays, MTT 3-(4,5-dimethylthianol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT), siRNAs for MUC4 (Cat.No.:AM 16708), and the oligofectamine transfection 
kit were obtained from Thermo Fisher Scientific (Watham, MA,USA). Mouse MUC4 monoclonal IgG1 anti-
body was ordered from Santa Cruz Biotechnology (Cat.No.:sc-33654; Dallas, TX, USA). Guinea pig vimentin 
polyclonal antibody was ordered from Fitzgerald Industries International (Cat.No.:20R-VP044, Acton, MA, 
USA). Texas Red-AffiniPure Goat anti Guinea Pig IgG secondary antibody was from Jackson ImmunoResearch 
Laboratories, Inc. (Cat.No.:106-075-003; Cambridgeshire, UK). Technical Manual Cell Counting Kit-8 (CCK) 
was obtained from Dojindo Molecular Technologies (Rockville, MD, USA). Glycodeoxycholic acid (GDCA) 
was from Cayman Chemical Company (Michigan, MI, USA). BAs (glycocholic acid (GCA); taurocholic acid 
(TCA); taurodeoxycholic acid (TDCA); glycochenodeoxycholic acid (GCDCA); taurochenodeoxycholic acid 
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(TCDCA)) and all other laboratory chemicals were ordered from Sigma-Aldrich Kft. (Budapest, Hungary). For 
more details on gene expression assays see Suppl. Table S1.
Cell lines and culture conditions. The human PDAC cell lines, Capan-1, Miapaca-2, Panc-1 and BxPC-3 
were obtained from American Type Culture Collection (Manassas, VA, USA). Capan-1 and BxPC-3 cells were 
cultured in RPMI-1640 media supplemented with 15% (v/v) fetal bovine serum (FBS); 1% (v/v) L-glutamine and 
2% (v/v) antimycoticum/antibioticum. Miapaca-2 and Panc-1 were maintained in Dulbecco’s Modified Eagle’s 
Medium high glucose medium supplemented with 10% (v/v) FBS, 1% (v/v) l-glutamin, 2.5% (v/v) horse serum, 
and 1% (v/v) pencillin/streptomycin. HPDEC, human pancreatic ductal epithelial cell line was ordered from 
Hölzel Diagnostika Handels GMBH (Köln, Germany) and the cells were cultured in keratinocyte serum-free 
media supplied with prequalified human recombinant Epidermal Growth Factor and Bovine Pituitary Extract. 
The cells were cultured under standard conditions (37 °C and 5%  CO2) the medium was replaced in every alter-
nate day and the cells were cultured at 100% confluence. Capan-1 cells were used between 30 and 35, BxPC-3 
cells between 2 and 5, Panc-1 and Miapaca-2 cells between 20 and 25 and HPDEC cells between 9 and 11 passage 
numbers.
Table 1.  Clinicopathological characteristics of pancreatic cancer patients selected for serum bile acid 
measurements.
Variable
PDAC + OJ (n = 10) PDAC (n = 5) NORMAL (n = 14)
n (%) n (%) p value n (%) p value
Gender
Male 5 (50.0) 2 (40.0) 6 (42.9)
Female 5 (50.0) 3 (60.0) 0.7376 8 (57.1) 0.9930
Age
˂65 2 (20.0) 0 (0.0) 10 (71.0)
 ≥ 65 8 (80.0) 5 (100.0) 0.5877 4 (29.0) 0.7125
Location of primary tumor
Papilla of Vater 3 (30.0) 0 (0.0)
Head 4 (40.0) 5 (100.0)
Head/Body 2 (20.0) 0 (0.0)
Body 1 (10.0) 0 (0.0)
Tail 0 (0.0) 0 (0.0) 0.4369
Hystological type
Well differentiated 0 (0.0) 0 (0.0)
Moderately differenti-
ated 7 (70.0) 5 (100.0)
Poorly differentiated 3 (30.0) 0 (0.0) 0.5599
Stage of the cancer
II 0 (0.0) 0 (0.0)
III 4 (40.0) 4 (80.0)
IV 6 (60.0) 1 (20.0) 0.4456
Lymphatic invasion
Negative 7 (70.0) 5 (100.0)
Positive 3 (30.0) 0 (0.0) 0.5166
Metastasis
Lung 0 (0.0) 0 (0.0)
Liver 4 (40.0) 3 (60.0)
Colon 1 (10.0) 2 (30.0)
Gall bladder 0 (0.0) 0 (0.0) 0.6540
Bile acids in human serum (ng/ml)
GCA 9890.5 ± 3267.1 (27.43) 41.46 ± 53.45 (5.65) 27.35 ± 26.66 (6.82)
GDCA 217.22 ± 193.27 (0.62) 67.83 ± 93.28 (9.25) 70.01 ± 86.59 (17.44)
GCDCA 4770.8 ± 2375.1 (13.23) 339.93 ± 376.6 (46.31) 186.77 ± 108.37 (46.54)
TCA 13,299 ± 2827.1 (36.88) 98.96 ± 57.09 (13.49) 0.0 ± (0.0)
TDCA 0.0 ± (0.0) 47.6 ± 27.4847.6 ± 27.48 (6.48) 61.32 ± 53.02 (15.28)
TCDCA 7878.1 ± 1644.3 (21.84) 138.07 ± 126.27 (18.81) 55.85 ± 31.55 (13.92)
Total serum bile acids 36,055.7 ± 2182.2 733.85 ± 118.7 0.0275 401.3 ± 35.38 0.0228
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Bile acid treatment. The cells were seeded into 25  cm2 tissue culture flasks or 96-well tissue plates, two 
days before the BAs treatment. The treatment was performed with six different types of BAs (GCA, TCA, GDCA, 
TDCA, GCDCA, TCDCA) in two different concentrations (100 and 500 µM), for 24, 48 and 72 h. Bile acid cock-
tail (BAC) contained all BAs in equal concentrations, with a final concentration of 500 µM.
Cell adhesion assay. We coated 96-well tissue plates with 40 µg/ml type 1 collagen from rat-tail in PBS at 
4 °C. Next, we added 100 µl of cell suspension  (105 cells/ml) to each of the coated wells and incubated the cells 
at 37 °C for 20 min to allow them to adhere to the surface. After washing, the cells were incubated with BAs and 
10 µl of MTT substrate was added to each well. MTT-treated cells were then lysed in DMSO and absorbance was 
measured using a FLUOstar OPTIMA Spectrophotometer (BMG Labtech, Ortenberg, Germany) at 560 nm with 
background subtraction at 620 nm.
Proliferation. For proliferation, 100 µl of cell suspension was seeded into a 96-well plate (5 × 103 cells/well), 
then the cells were incubated with BAs. After the treatments, 10 µl of CCK8 solution was added to each well 
and the cells were incubated for further 3 h. We measured absorbance at 450 nm using a FLUOstar OPTIMA 
Spectrophotometer (BMG Labtech, Ortenberg, Germany).
Cytotoxicity assay. For cytotoxicity assay, 100 µl of cell suspension was seeded into a 96-well plate (2 × 104 
cells/well) and allowed to adhere overnight. On the following day, the cells were incubated with BAs then 100 µl 
supernatant from each of the wells was carefully transferred into a new 96-well plate containing 100 µl reac-
tion mixture. We then measured lactate dehydrogenase (LDH) activity at 490 nm using a FLUOstar OPTIMA 
Spectrophotometer (BMG Labtech, Ortenberg, Germany). For background controls, we measured 200 µl assay 
medium, without cells. For low controls, we used 100 µl cell suspension and 100 µl assay medium. In the case 
of high controls, the mixture of 100 µl cell suspension and 100 µl Triton-X 100 (0.1%) solution was measured. 
The LDH release induced by Triton-X 100 was assigned to 100%. The average absorbance values of each of the 
triplicates were calculated and the average value of the background control (LDH activity contained in the assay 
medium) was subtracted from each of the samples to reduce background noises. We then calculated the per-
Table 2.  Clinicopathological characteristics of pancreatic cancer patients selected for MUC4 staining.
Variable
PDAC + OJ 
(n = 25) PDAC (n = 25) NE (n = 11)
NORMAL 
(n = 4)
n (%) n (%) n (%) n (%)
Gender
Male 13 (52.0) 17 (68.0) 8 (72.7) 1 (25.0)
Female 12 (48.0) 8 (32.0) 3 (27.3) 3 (75.0)
Age
˂ 65 6 (24.0) 10 (40.0) 4 (36.36) 4 (100.0)
 ≥ 65 19 (76.0) 15 (60.0) 7 (63.64) 0 (0.0)
Location of primary tumor
Papilla of Vater 3 (12.0) 0 (0.0) 0 (0.0)
Head 22 (88.0) 18 (72.0) 6 (54.54)
Head/Body 0 (0.0) 5 (20.0) 0 (0.0)
Body 0 (0.0) 1 (4.0) 1 (9.1)
Tail 0 (0.0) 1 (4.0) 4 (36.36)
Hystological type
Well differentiated 3 (12.0) 3 (12.0) 4 (36.37)
Moderately differentiated 12 (48.0) 18 (72.0) 7 (63.63)
Poorly differentiated 10 (40.0) 4 (16.0) 0 (0.0)
Stage of the cancer
II 2 (8.0) 4 (16.0) 8 (72.73)
III 10 (40.0) 12 (48.0) 3 (27.27)
IV 13 (52.0) 9 36.0)
Lymphatic invasion
Negative 17 (68.0) 20 (80.0) 11 (100.0)
Positive 8 (32.0) 5 (20.0) 0 (0.0)
Metastasis
Lung 2 (8.0) 4 (16.0) 0 (0.0)
Liver 6 (24.0) 10 (40.0) 2 (18.18)
Colon 0 (0.0) 2 (8.0) 0 (0.0)
Gall bladder 1 (4.0) 0 (0.0) 0 (0.0)
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centage of cytotoxicity using the following formula: Cytotoxicity (%) = (exp. value–low control/high control-low 
control)*100. Low control determines the LDH activity released from the untreated normal cells (spontaneous 
LDH release), whereas high control determines the maximum releasable LDH activity in the cells (maximum 
LDH release).
Wound healing assay. Cells were seeded onto 24-well cell culture plates in a 2.5 × 105 cell density and 
allowed to adhere overnight. On the following day, the confluent monolayer was gently scratched using P2 tips. 
Only the wells containing even-sided and sharp-edged wounds were used for experiments. After gentle washing 
with the complete medium, we added BAs to the wells. We carried out automated time lapse imaging using an 
Olympus IX83 inverted microscope with Olympus ScanR screening platform (Olympus, Japan) upgraded with 
OKOLAB incubator system (with gas, temperature, and humidity controller; Pozzuoli, NA, Italy). Digital images 
were analysed by Image J.
Clonogenic assay. Capan-1 and BxPC-3 cells  (103 cells/well) were seeded onto 6-well cell culture plates and 
allowed to adhere overnight. On the following day, the cells were treated with BAs then the normal media was 
given back. The cells were allowed to grow until day 9 after which the media was removed, and the cells were 
washed with PBS, fixed with methanol-ethanol solutions (3:1 dilution) and then stained with Giemsa. Olympus 
IX83 microscope-based screening platform was used for image acquisition and the Olympus Cellsense Dimen-
sion software was used for automated object detection, classification and measurement to enumerate colonies 
organised by the treated and untreated cells.
Invasion assay. For the invasion assay Matrigel-coated transwell inserts were used. 200 µl cells (~ 2.5 × 105/
ml in serum-free medium) were added into the inserts whereas the lower chambers contained 750 µl complete 
medium with or without BAs. Cells were than incubated at 37 °C for 24–72 h in 5%  CO2 in a humidified incuba-
tor. Cells that migrated to the bottom surface were fixed in formaldehyde (3.7% in PBS) for 5 min, permeabilized 
with 100% methanol and stained with Giemsa dye for 30 min. The non-invading cells on the upper surface of the 
membrane were gently scraped off using a cotton swab. Invasion was quantified by counting the average number 
of invaded cells in five different microscopic fields in each treatment. Percent invasion was calculated from the 
mean of the average number of invaded cells obtained from 3 independent experiments.
siRNA silencing. MUC4 expression was silenced transiently, using MUC4-targeted siRNA oligonucleo-
tides. Transfection was performed with Oligofectamine™ Transfection Reagent following the manufacturer’s 
instructions. We then plated 2 × 105 cells per well onto 6-well plates a day before the transfection. At 50–60% 
confluency, the MUC4-targeted siRNAs were transfected and the cells were incubated for 72 h. MUC4 mRNA 
and protein levels were assessed by RT-PCR and immunocytochemistry, respectively.
RT-PCR. The total RNA was isolated from the cells using the NucleoSpin RNA Kit (Macherey–Nagel, Düren, 
Germany). Two micrograms of RNA were reverse-transcripted using the High-Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems, Foster City, USA). Real-time PCR reactions of samples were performed with 
TaqMan RT-PCR assays (Supplementary Table S1) from Thermo Fisher Scientific (Darmstadt, Germany). Reac-
tions were carried out with ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, 
USA) platform with the following conditions: 10 min initial denaturation at 95 °C, followed by 40 steps cycles: 
15 s at 95 °C and 1 min at 60 °C. Fluorescein dye (FAM) intensity was detected after each cycle. All the samples 
were run in triplicates and non-template control sample was used for each PCR run to check the primer-dimer 
formation. The expression level of the gene of interest was normalised to the human β-actin (Actb) housekeep-
ing gene (ΔCT), and then relative gene expression ratios were calculated using the ΔΔCT method as previously 
 described26,27. The results were expressed as fold changes  (2−ΔΔCT). Genes with expression values less than or 
equal to 0.5 were considered to be down-regulated, whereas the values higher than or equal to 2 were considered 
to be upregulated. Values ranging from 0.51 to 1.99 were not considered to be significant.
Immunostainings. Immunocytochemistry (ICC) was performed using cytospin preparation during which 
100 µl (2 × 106 cells/ml) of cell suspension was added to 100 µl of neutral formalin buffer and incubated for 5 min. 
After the incubation, 100 µl from this mixture were spin (Shandon Cytospin3, Marshall Scientific, Cambridge, 
MA, US) to an Ultra Plus Microscope Slide (Thermo Fisher Scientific, Darmstadt, Germany). Pre-treatment was 
carried out with heat-induced epitope retrieval procedure using PT Link (Autostainer Link 48, Agilent, Dako, 
Santa Clara, CA, US) with EnVision ™ Flex Target Retrieval Solution for 20 min at 92 °C in low pH (pH 6,1; cit-
rate buffer). Slides were then washed with EnVision™ Wash Buffer (20 ×) for 5 min. The endogenous peroxidase 
blocking was carried out with EnVision™ Flex Peroxidase Blocking Reagent. For staining procedure, the slides 
were incubated with MUC4 (1:100 dilutions) primary antibodies for 30 min. After incubation, the slides were 
washed and incubated with secondary antibody (EnVision™ Flex/HPR anti-mouse/rabbit) for 30 min. For visu-
alisation, the Ultra View Universal diaminobenzidine (DAB) Detection Kit (EnVision™ Flex DAB) was applied 
and nuclear staining was carried out with EnVision™ Flex Hematoxylin. After the staining procedure, the slides 
were mounted with Xylene Substitute mount (Shandon, Marshall Scientific, Cambridge, MA, US). All specimens 
were scanned by the Olympus IX83-based system and the pictures were further analysed by ImageJ, whereas 
the intensities of the pixels of the DAB staining were quantified. In the case of vimentin staining, Capan-1 cells 
(20,000/chamber) were seeded on chamber slides, fixed with 3.6% paraformaldehyde and permeabilized with 
0.2% Triton X-100 and 0.3% protease-free bovine serum albumin. Cells were then incubated with 10% donkey 
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serum to reduce non-specific binding than anti-vimentin primary antibody (1:100 dilution) was added to the 
chambers and slides were incubated overnight in moist atmosphere at 4 °C. Chamber slides were then washed 
with PBS and incubated with TexasRed-conjugated anti-mouse secondary antibody (1:400 dilution) for 60 min 
at RT. Nuclei were counterstained with Hoechst 33342. Slides were then mounted and observed by a Fluowiew 
10i-W confocal microscopy (Olympus, Budapest, Hungary). In the human pancreatic samples, MUC4 expres-
sion was analysed using formalin-fixed, and paraffin-embedded tissue specimens were obtained from patients. 
Control tissues (n = 4) were collected from the tumour-free region of the pancreas of patients with NE tumour. 
Briefly, 3 to 4 µm thick sections of section specimens were deparaffinised in xylene and rehydrated in graded 
ethanol. The diagnosis was assessed by a pathologist after staining the sections with haematoxylin–eosin–saf-
fron. Immunohistochemistry (IHC) was performed as described above, but the slices were incubated with the 
primary MUC4 antibody for 60  min. Quantification of MUC4 expression was evaluated using the method 
described by Rachagani et al.28.
LC–MS measurement of the serum samples. The measurement of BAs was based on the work of Ghaf-
farzadegan et al. with slight  modifications29. The stock solution contained 1 mg/ml of each BA in methanol was 
used to form a seven-point calibration curve ranging from 5–1000 ng/ml determining the concentration of BA 
in serum samples. In the calibration solutions the concentration of internal standard (IS) were set to 700 ng/
ml and 210  ng/ml for GCDA-D4 (used for TCA, GCA, GCDA and GDCA) and DCA-D4 (used for TDCA 
and TCDCA), respectively. The frozen serum samples were allowed to thaw at 25 °C, then 50 µl of each was 
spiked with 175 µl methanol, containing IS in 400 ng/ml (GCDA-D4) and 120 ng/ml (DCA-D4). Samples were 
vortexed (LSE W, Corning, USA) for 1 min then incubated for 30 min in -20 °C. The incubated samples were 
centrifuged (Heraus Fresco 17, Thermo Scientific, USA) at 13,000 rpm for 15 min in 10 °C. The supernatant was 
transferred to microcentrifuge tubes and evaporated with vacuum concentrator (Savant SC250EXP, Thermo 
Scientific, USA) at 40 °C and 1 mbar for 60 min. The residue was dissolved in 100 µl water and 5 µl was subjected 
to a Nexera XR UHPLC system (Shimadzu, Japan) coupled with a TSQ Quantum Access mass spectrometer 
(Thermo Scientific, USA). The separations were performed on a Purospher Star RP-18 Hibar HR 100 × 2.1 mm, 
2 µm reversed phase column (Merck KGaA, Germany) tempered at 50 °C. The solvent A was 0.1% formic acid in 
water and the solvent B was 0.1% formic acid in methanol:acetonitrile 1:1. The flow rate was 300 µl/min and the 
following gradient elution was applied: 0–0.5 min, 30% B; at 1.5 min, 50% B; at 9 min, 58% B; at 9.5 min 85% B; at 
12 min, 95% B; at 15 min, 95% B; at 15.5 min, 30% B; at 20 min, 30% B. The mass spectrometer operated in nega-
tive ionization mode using HESI ion source where the spray voltage was 3500 V, the vaporizer temperature was 
350 °C, the ion-transfer capillary temperature was 275 °C, the sheath gas pressure was 30 in arbitrary units and 
the aux gas pressure was 20 in arbitrary units. The BAs were detected in SRM mode using two mass transitions 
for each analyte at the following retention times: TCA (5.3 min, m/z 514.3 → 124.7/60.0), GCA (6.7 min, m/z 
464.3 → 402.3/75.60), TCDCA (7. 2 min, m/z 498.0 → 125.2/108.3), TDCA (7.9 min, m/z 497.9 → 125.2/108.3), 
GCDA (8.8 min, m/z 448.2 → 75.6/330.5), GDCA (9.6 min, m/z 448.3 → 402.3/75.6), DCA-D4 (11.9 min, m/z 
395.4 → 349.8/330.5) and GCDA-D4 (8.8 min, m/z 452.3 → 390.4/387.6). For the instrument control and the 
data evaluations, the TraceFinder 4.1 software (Thermo Scientific, USA) was applied.
Statistical analysis. Quantitative variables were described as means ± SE. Significant differences between 
groups were performed by ANOVA, p ≤ 0.05 were accepted as significant. Survival curves were prepared using 
the method of Kaplan and Meier, and differences in survival were studied by the Log-rank test.
Results
Serum levels of bile acids in PDAC patients. The total serum bile acid (TSBA) concentration in healthy 
controls was 401.3 ± 35.38 ng/ml, whereas in PDAC + OJ patients it increased tremendously (36,055.7 ± 2182.2 ng/
ml; Fig. 1A). Analysis of individual BAs has shown higher concentrations of GCA, TCA, GCDCA and TCDCA 
in the serum of PDAC + OJ patients. Interestingly, TCA was completely absent in healthy control, but increased 
dramatically in PDAC + OJ. Serum levels of TDCA were low in controls and could not be detected in PDAC + OJ 
patients (Fig. 1A). In PDAC patients without OJ, the TSBA concentration was 733.9 ± 118.7 ng/ml. Table 1 shows 
the clinicopathological characteristics and the level of BAs in human serum.
Bile acids play a key role in the progression of PC. In the next step, we treated Capan-1 cells for 24, 
48 and 72 h with serum obtained from PDAC patients (with or without OJ) and healthy volunteers (normal). 
Treatment with human serum induced a changed morphology and growth characteristic of the cells, therefore, 
we examined whether this altered morphology is associated with epithelial-mesenchymal transition (EMT). 
Vimentin is a structural protein that is expressed in mesenchymal cells but not in epithelial cells. In the case 
of PDAC + OJ a strong positive staining for vimentin was detected (Fig. 1B). In the PDAC group, only a slight 
staining was observed, whereas the control and the normal groups were completely negative for vimentin. These 
data indicate that BAs have a prominent role in the progression of cancer. To confirm this hypothesis, we sup-
plemented PDAC serum with 0.5 mM BAs cocktail (BAC). The concentration and composition of BAC were 
selected on the basis of serum BAs measurements. Supplementation of PDAC serum with BAC resulted in simi-
larly strong vimentin staining as observed for PDAC + OJ. As a positive control gastric myofibroblast were used. 
Moreover, we investigated proliferation, viability, and adhesion capability of the cells. As expected, serum from 
PDAC patients increased the rate of proliferation, adhesion and survival of Capan-1 cells compared to the nor-
mal serum (Fig. 1C–E.) Importantly, there was also a significant difference between the effect of serum from 
PDAC patients and that of PDAC + OJ patients, suggesting a specific role of BAs in PC pathogenesis.
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Bile acids promote proliferation, adhesion, invasion, migration and colony forming of pan-
creatic ductal adenocarcinoma cells. The role of individual BAs in cancer progression was investigated 
in two PDAC cell lines. Capan-1 and BxPC-3 cells were treated with different BAs and the proliferation and 
metastatic potential of the cells were investigated using different cell-based assays. Interestingly, most of the 
BAs decreased cell viability largely in normal pancreatic cell line (HPDEC) (Fig. 2A). The average cell deaths 
induced by 100 µM BAs were 28.35 ± 5.78% at 24 h, 51.03 ± 4.69% at 48 h and 40.91 ± 6.2% at 72 h, whereas the 
effects of 500 µM BAs were more pronounced (44.32 ± 5.54% at 24 h, 62.47 ± 5.32% at 48 h and 48.86 ± 5.3% at 
72 h). Low concentration (100 µM) of BAs were only slightly toxic to the Capan-1 cells; they induced cell death 
in approximately 16–20% of the cells. (Fig. 2A) The average cell death induced by 100 µM BAs was 16.98 ± 3.05% 
at 24 h, 18.82 ± 3.27% at 48 h and 20.20 ± 2.88% at 72 h. As the concentration of BAs increased (500 µM), the 
rate of cell death elevated depending on time. The average cell death induced by 500 µM BAs was 37.01 ± 5.91% 
at 24 h, 29.67 ± 5.79% at 48 h and 31.41 ± 1.19% at 72 h. Similar results were obtained with the BxPC-3 cell line.
Incubation of Capan-1 and BxPC-3 cells with BAs, increased the rate of proliferation almost in all treated 
groups (Fig. 2B). Among BAs, the effect of TDCA was dose-dependent especially at 24 h; it suppressed prolifera-
tion of the cells (0.83 ± 0.06) at a low concentration (100 µM), and increased it (1.64 ± 0.02) at a high concentra-
tion (500 µM), depending on time. Binding of cells to extracellular matrix plays an important role in survival of 
cells and determines the progression and outcome of PC. Subsequently, we have investigated the effect of BAs 
treatment on the adhesion of Capan-1 and BxPC-3 cells to collagen 1. As shown in Fig. 2C, adhesion of cells 
increased with the incubation time, mainly at high doses of TCDCA-treated group. BAs treatment also promoted 
the invasion of Capan-1 and BxPC-3 cells, as demonstrated on Fig. 2D,E. We have also investigated the meta-
static potential of cancer cells using the wound healing assay. Treatment with BAs, especially high concentration 
of TCDCA (500 µM), significantly increased the migration rate of both Capan-1 and BxPC-3 cells (Fig. 2F). 
Next, we have investigated the ability of Capan-1 and BxPC-3 cells to form colonies using the clonogenic assay. 
Figure 3A shows a representative picture regarding the effect of TCDCA at high (500 µM) concentration. These 
pictures and the summary bar chart (Fig. 3B) clearly show that high concentration of BAs increase the colony 
forming ability of the cells especially at 72 h. We have also investigated the size of the colony in differently treated 
groups (Fig. 3C–E). Furthermore, we have distinguished the colonies according to the following criteria: small: 
1000–10,000 µm2, medium: 10,000–20,000 µm2, large: 20,000–30,000 µm2 and extra-large: 30,000–100,000 µm2. 
In the case of small colonies, a number of colonies were significantly higher in the non-treated, control group, 
compared to the BA-treated groups. Medium-sized colonies did not show any difference between the BA-treated 
and control groups. In contrast, BA treatment significantly increased the number of colonies in the large and 
Figure 1.  Serum levels of bile acids in pancreatic cancer patients and the effect of serum on Capan-1 cells. 
(A) Serum levels of bile acids (BAs) in healthy volunteers and pancreatic ductal adenocarcinoma patients 
(PDAC) with or without obstructive jaundice (OJ) were measured by LC–MS. GCA glycocholic acid, TCA 
taurocholic acid, GDCA glycodeoxycholic acid, TDCA taurodeoxycholic acid, GCDCA glycochenodeoxycholic 
acid, TCDCA taurochenodeoxycholic acid. N.D. not detected. (B) Capan-1 cells were treated with human 
serum obtained from healthy volunteers and PDAC patients and the expression of vimentin was investigated 
by immunocytochemistry. Control (Ctrl) samples were treated with culture medium only. As a positive control 
gastric myofibroblasts were used. The rate of proliferation (C), adhesion (D) and viability (E) was measured in 
Capan-1 cells. a = p ≤ 0.05 vs. Control, b = p ≤ 0.05 vs. PDAC. BAC bile acid cocktail, TRX Triton-X-100.
8
Vol:.(1234567890)
Scientific Reports |        (2020) 10:22088  | https://doi.org/10.1038/s41598-020-79181-6
www.nature.com/scientificreports/
extra-large groups, indicating that BAs induce the formation of large and extra-large colonies both in the Capan-1 
(Fig. 3D) and BxPC-3 (Fig. 3E) cells, an action that promotes larger tumour tissue development.
Expression of mucin genes in pancreatic ductal cell lines. Our results clearly demonstrate that BAs 
accelerate tumour processes; thus, we aimed to identify the mechanism that mediates the effects of BAs. Mucins 
are glycoproteins whose significance has been identified in many cancer types. To examine whether BAs are 
acting through the altered mucin expression, we investigated the effect of BAs on mucin expression. First, we 
studied the mRNA expression of mucin genes in HPDEC, Capan-1 and BxPC-3 cells using RT-PCR and TaqMan 
primer–probe sets, specific for mucin genes (Suppl. Table S1). We have investigated those genes (MUC1, -2, -4, 
-5AC, -5B, -12, -13, -15 -17, -19 and -20), which are proved to play a central role in gastrointestinal tumours, and 
TaqMan probe sets were available for them. In the normal cell line, the presence of MUC1, -2, -17 and -20 was 
shown (Table 3). In the case of Capan-1, expressions of MUC1, -4, -5AC, -5B, -13, -17 and -20 were observed, 
whereas in the BxPC-3 cells the presence of MUC1, -2, -4, -5AC, -5B and -13 was detected. Mucin expressions 
were also tested in two other PDAC cell lines, PANC-1 and MIAPaCa-2. Interestingly, much less mucin genes 
were detected in these cell lines (Table 3). The mucin genes used as a biomarker in PC, such as MUC4, -5AC and 
-5B, are expressed only in Capan-1 and BxPC-3 cells. The expression of mucin genes is summarised in Table 3.
Effect of bile acids on mucin expression. In the next step, we pre-treated the cells with various BAs (100 
and 500 µM) for 24, 48 and 72 h and the mRNA expression of mucin genes was investigated by RT-PCR. In the 
normal cell line, long time incubation with the BAs decreased the expression of MUC1 and -2 in most of the 
treated groups (Suppl. Fig. S1A). In contrast, all of the investigated BAs dose-dependently increased the expres-
sion of MUC20 (Suppl. Fig. S1A). Treatment with BAs did not affect the expression of the other genes (data 
not shown). In the Capan-1 cell line, BAs treatment dose- and time-dependently upregulated the expression of 
MUC4 (Fig. 4A). Among the BAs, the highest effect has the conjugated forms of DC and CDC acids. In contrast, 
GCA and TCA induced significant increase only at higher concentrations. Interestingly, TCDCA induced a 
robust increase (approx. fivefold compared to the control) in the expression of MUC17 at a high concentra-
tion (500 µM), at all three incubation times (Supp. Fig. S1B). The expression of the other genes did not change 
Figure 2.  Effects of bile acid treatment on cell viability, proliferation, adhesion, invasion and migration. 
Capan-1 and BxPC3 cells were exposed to different concentration of bile acids (BAs) for 24, 48 and 72 h and 
the effects on cellular viability (A), proliferation (B), adhesion (C), invasion (D,E) and migration (F) were 
studied using different assays, as described in Materials and Methods. In the case of viability assay, as a positive 
control, 0.1% Triton-X-100 (TRX) was used. The rate of migration was investigated by the wound healing assay. 
Photography was taken at 0, 24, 48 and 72 h after TCDCA (500 µM) treatment using Olympus IX83 inverted 
microscope (Olympus cellSense Dimension software version 2.3, https ://www.olymp us-lifes cienc e.com/en/softw 
are/cells ens/) and the rate of wound closure was expressed as % of migration at 72 h. Data represent mean ± SEM 
of three, independent experiments. * = p ≤ 0.05 vs. Control. GCA glycocholic acid, TCA taurocholic acid, 
GDCA glycodeoxycholic acid, TDCA taurodeoxycholic acid, GCDCA glycochenodeoxycholic acid, TCDCA 
taurochenodeoxycholic acid. Orange indicates Capan-1whereas red BxPC-3 cells.
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significantly in most of the groups (Supp. Fig. S1B). Similarly to the Capan-1 cells, BAs treatment increased the 
expression of MUC4 in the BxPC-3 cell line (Fig. 4A), however it did not or hardly affect the expression of the 
other genes (Suppl. Fig. S1C). MUC4 has been shown to be aberrantly expressed in PC; it promotes metastasis, 
and it is used as a prognostic factor; thus, we investigated the expression of this gene also at a protein level. Using 
immunostaining, we have shown that, similar to the RT-PCR data, pre-treatment with BAs time- and dose-
dependently increased the protein expression of MUC4 in both PDAC cell lines (Fig. 4B,C).
Hierarchical clustering of genes showed that TDCA, TCDCA, GCDCA and GCA (in high concentration) 
initiated similar MUC gene expression level changes in both cell lines and formed a separated cluster from the 
other BAs. The expression pattern of MUC2, -4 and -17 has changed more pronouncedly than the other genes 
Figure 3.  Effects of bile acid treatment on the colony forming of Capan-1 and BxPC-3 cells. Cells were exposed 
to different concentration of bile acids (BAs) and the colony forming ability of the cells was investigated by the 
clonogenic assay. (A) Representative pictures show the effect of taurochenodeoxycholic acid (TCDCA; 500 μM) 
at 24, 48 and 72 h. (B) Quantification of the colonies was performed using an Olympus IX83 microscope-
based screening platform (Olympus cellSense Dimension software version 2.3, https ://www.olymp us-lifes 
cienc e.com/en/softw are/cells ens/). (C–E) For the classification and counting of the colonies an automatic 
Olympus Cellsense Dimension software was used. (C) Representative images showing colonies for each cell line. 
Summary diagrams for Capan-1 (D) and BxPC-3 (E) cells. Data represent mean ± SEM of three, independent 
experiments. * = p ≤ 0.05 vs. Control. GCA glycocholic acid, TCA taurocholic acid, GDCA glycodeoxycholic acid, 
TDCA: taurodeoxycholic acid, GCDCA glycochenodeoxycholic acid, TCDCA taurochenodeoxycholic acid.
Table 3.  mRNA expression of mucin genes in the different pancreatic ductal cell lines.
Isoforms Capan-1 BxPC-3 MiaPaca-2 Panc-1 HPDEC
MUC1 ✓ ✓ ✓ ✓ ✓
MUC2 – ✓ – ✓ ✓
MUC4 ✓ ✓ – – –
MUC5AC ✓ ✓ – – –
MUC5B ✓ ✓ – – –
MUC12 – – ✓ ✓ –
MUC13 ✓ ✓ – – –
MUC15 – – – – –
MUC17 ✓ – – – ✓
MUC19 – – – – –
MUC20 ✓ – ✓ – ✓
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upon BAs treatments, which suggest that these genes are more sensitive to BAs. Deeper analysis focusing on 
just the Capan-1 cell line showed that MUC4 pattern changed only after 48 h of the BAs treatment (Fig. 4D).
Expression of MUC4 in human pancreatic samples. The presence of MUC4 has also been investi-
gated in human pancreatic samples by IHC. In the normal pancreas and in NE, there was no detectable staining 
for MUC4 (Fig. 5A). In contrast, in the case of PDAC (with or without OJ), we observed a strong expression of 
MUC4 in the intra- and interlobular ducts. Interestingly, in those patients where PDAC was diagnosed without 
OJ, the expression of MUC4 was significantly low compared to the PDAC + OJ group. (Fig. 5B) There was no 
significant difference in gender, age, location of primary tumour, histological type, stage, lymphatic invasion or 
metastasis between the PDAC and PDAC + OJ groups (Table 2). In addition, in the PDAC + OJ group the expres-
sion of MUC4 increased with the progression of the disease, whereas in the PDAC group, there was no differ-
ence in the expression of MUC4 between the early and advanced stages. Quantification of the staining has been 
shown in Fig. 5B. We also examined how high serum levels of bile affects the outcome of PC. The 4-year overall 
survival rate of the PDAC + OJ group was significantly lower than that of the PDAC group (p = 0.0191) (Fig. 6).
Knockdown of MUC4 decreases the carcinogenic effect of BAs. Next, we have investigated the 
effect of MUC4 knockdown on the proliferation of Capan-1 and BxPC-3 cells. MUC4 was silenced by MUC4-
specific siRNA. The efficiency of MUC4 knockdown was confirmed by RT-PCR (Fig. 7A) and ICC (Fig. 7B). 
We found that knockdown of MUC4 significantly increased cell death and decreased the rate of proliferation, 
adhesion, migration and colony forming in a time-dependent manner. (Fig. 7C-G) These results indicate that 
MUC4 is key mucoprotein in the growth of PDAC cells. In the next step we tested the effect of BAs on the 
MUC4-silenced cells. Among BAs, the effect of TCDCA was investigated, as this BA showed the greatest effect 
on both Capan-1 and BxPC-3 cells. When TCDCA was added in the absence of MUC4, an increase in the above-
mentioned parameters has been observed, although it was still significantly lower than in the presence of MUC4, 
indicating that the effect of BAs is mediated by MUC4, although other factors also play a role in it (Fig. 7C-G 
and Suppl. Fig. S2.).
Figure 4.  Effects of bile acid treatment on the mRNA and protein expression of mucins in pancreatic 
ductal cells. (A) Capan-1 and BxPC-3 cells were treated with different bile acids (BAs) for 24, 48 and 72 h 
and the relative gene expressions of MUC4 gene was investigated by real-time PCR. (B) Representative 
immunofluorescence staining of Capan-1 and BxPC-3 cells shows the expression of MUC4 after the treatment 
with taurochenodeoxycholic acid (TCDCA; 500 μM) for 24, 48 and 72 h. (C) Quantification of MUC4 protein 
expression. Specimens were scanned using Olympus IX83 based system (Olympus cellSense Dimension 
software version 2.3, https ://www.olymp us-lifes cienc e.com/en/softw are/cells ens/) and DAB staining intensities 
were analysed by ImageJ software. Data represent mean ± SEM of three, independent experiments. * = p ≤ 0.05 
vs. Control. Scale bar represents 100 µm. (D) The cluster analysis and dendrogram show the difference between 
the effect of BAs treatment at different concentrations and time points. Red and white colours indicate high 
and low expression, respectively. (Values represent the fold change in the gene expression level of MUC genes). 
Data represent mean ± SEM of three, independent experiments. GCA glycocholic acid, TCA taurocholic acid, 
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Discussion
Since most of the PCs develop in the head of the pancreas, PDAC is frequently associated with increased levels 
of BAs in the serum; however, the effect of bile on PC progression has not been evaluated yet. In this study, we 
used two PDAC cell lines to show that BAs promote carcinogenic processes in which expression of MUC4 plays 
a huge role.
We have shown that the serum levels of BAs extremely increase in PDAC + OJ patients and the most abundant 
BAs are GCA, TCA, GCDCA and TCDCA. In order to investigate how elevated serum bile influences carcino-
genic processes, a PDAC cell line, Capan-1 was treated with serum obtained from PDAC patients. Capan-1 is 
Figure 5.  Expression of MUC4 in human pancreatic samples. (A) Representative immunohistochemical 
stainings show the presence of MUC4 in human pancreatic samples. (B) Composite scores of human pancreatic 
samples stained with anti-MUC4 antibody. Data represent mean ± SEM of 23–25 specimens/4–25 patients each 
group. a = p ≤ 0.05 vs. normal, b = p ≤ 0.05 vs. PDAC, c = p ≤ 0.05 vs. advanced stage. Scale bar represents 100 µm. 
PDAC pancreatic ductal adenocarcinoma; OJ obstructive jaundice; NE neuroendocrine tumour.
Survival rate (%)
N 1-yr 2-yr 3-yr 4-yr
PDAC 25 100.0 56.0 21.1 4.0
PDAC+OJ 25 76.0 32.0 8.0 0.0


















Log rank P = 0.0191
Figure 6.  Survival curves of PDAC patients. The 4-year overall survival rate was significantly poorer in the 
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one of the most aggressive commercially available cell line; therefore, it proved to be a good model for the char-
acterisation of PC  progression30. High concentration of bile in the serum enhanced the tumorigenic potential 
of Capan-1 cells and also promoted EMT, indicating that BAs play a prominent role in the pathomechanism of 
PC. Previous studies indicated that the structure (number of –OH groups or the conjugation with glycine or 
taurine) of individual BAs determines their carcinogenic  effect31. Moreover, the studies show that hydropho-
bic bile acids are mostly toxic to cells, by generating oxidative stress and DNA damage, while hydrophilic bile 
acids play a protective  role32. In this study, we focused on those BAs that we detected in the serum of PDAC 
patients and literature data also confirm their altered concentrations in both the serum and pancreatic juice of 
PC  patients12,15,16. In terms of cell survival, the normal and PC cells reacted differently to BAs. In normal cells, 
the higher rate of cell death was observed, especially after 48 h of BAs treatment, which indicates that, under 
normal conditions, the ductal cells respond by cell death to this noxious agent. Similar results have been shown 
on isolated, guinea pig pancreatic ducts, where the treatment of ducts with high dose (1 mM) of CDCA damaged 
the mitochondria and induced apoptosis in the ductal  cells32. The apoptotic effect of BAs on normal epithelial 
cells has also been demonstrated in hepatocytes and in oesophageal and nasopharyngeal epithelial  cells33–35. We 
hypothesised that the bile-induced cell death in the normal cells is an anti-cancer defence, by which the malig-
nant transformation of the cells can be avoided. In contrast, cancer cells were more resistant to BAs treatment. 
Long-term incubation of Capan-1 and BxPC-3 cells with BAs increased their survival, which was consistent with 
the increased proliferation rate of these cells. The different response of normal and PDAC cells to BAs treatment 
can be explained by the fact that BAs are more likely to induce DNA damage than apoptosis in cancerous cells. 
Since gene mutations are more frequent in the damaged DNA, this favours the tumour  progression36. In contrast, 
some studies have found that BAs treatment inhibit the proliferation of pancreatic cancer cell lines (PANC-1 
and MIAPaCa-2) due to the cytotoxic effects of  BAs13,14. In these studies, relatively low concentrations (< 50 µM) 
of BAs were used and that might cause the difference. This is also proved by the fact that, among the BAs we 
investigated, the effect of TDCA was dose-dependent. High concentration of this BA promoted proliferation, 
and low concentration strongly inhibited it. The dose-dependent effect of the unconjugated form of TDCA has 
also been shown on colonocyte’s37 and in gastric and oesophageal  carcinoma38,39; however, the exact explanation 
is unknown. In addition, we have found that the adhesion, invasion, migration and colony forming ability of 
Capan-1 and BxPC-3 cells increased due to the BAs treatment, indicating that BAs enhance both the migratory 
and cell growth potential of PDAC cells. In the following, we wanted to identify the mechanism by which BAs 
exert their effects. Mucins can be found throughout the whole body, where they provide the hydration and lubri-
cation of the mucosal surfaces and their pivotal role in different cancer types is generally  known40. Depending on 
the tissue type, some of the genes act as a tumour suppressor and some of them promote tumour development 
Figure 7.  Knockdown of MUC4 in Capan-1 cells. The expression levels of MUC4 was investigated by RT-PCR 
(A) and immunohistochemistry (B) in control cells and in cells treated with specific siRNA for MUC4. 
Orange indicates Capan-1 whereas red BcPC-3 cells. The rate of viability (C), proliferation (D) and adhesion 
(E) was determined at 24, 48 and 72 h, whereas migration (F) and colony forming (G) at 72 h. Data represent 
mean ± SEM of three, independent experiments. a = p ≤ 0.05 vs. Control, b = p ≤ 0.05 vs. MUC4 KD, c = p ≤ 0.05 
vs. MUC4 KD + TCDCA. TCDCA: taurochenodeoxycholic acid, KD: knock down.
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or  growth16,18–20,41. MUC4 is a transmembrane mucin, which has an outstanding role in PC. The expression of 
this gene dramatically increases in PC and the overexpression of MUC4 is associated with poor  prognosis18,41,42. 
We used RT-PCR to show the presence of MUC4 in Capan-1 and BxPC-3 cells, but not in the normal cell line 
or in the other two PDAC cell lines. Besides MUC4, expression of MUC1, -5AC, -5B, -13, -17 and -20 have 
been shown in Capan-1 and the expression of MUC1, -2, -17 and -20 in the normal cells. The different expres-
sion pattern of mucins in normal and PDAC probably plays important role in cancer development. A tumour 
suppressor role of MUC2 has been shown in pancreatic  neoplasia43, whereas overexpression of MUC1 and -20 
correlated with poor survival in PDAC  patients43,44. MUC5AC, -5B and -13 are absent in normal pancreas, but 
can be detected in pancreatic intraepithelial neoplasia and  PDAC45. The role of MUC17 is controversial. Some 
data indicate that MUC17 decreases the tumorigenic potential of PDAC  cells46, whereas others have found that 
this gene is aberrantly expressed in  PC47,48.
In the normal cell line, BAs treatment decreased the expression of MUC2, and upregulated MUC20. Since 
MUC2 is a tumour suppressor, whereas overexpression of MUC20 favours tumour progression, these data 
indicate that BAs facilitate tumour development under normal conditions, by altering the expression of these 
mucins. In contrast, the expression of other, oncogenic mucins, such as MUC4, did not change due to the BAs 
treatment. In the Capan-1 and BxPC3 cell lines, BAs induced changes in the expression of MUC4 and at least 
two days of BAs treatment were needed to detect changes in its expression pattern. The expression of MUC17 
was only affected by high concentration of TCDCA in the Capan-1 cells and it could be detected 24 h after the 
treatment. Using human pancreatic samples, we showed that MUC4 was completely abolished from the normal 
pancreatic tissue and also in NE. In contrast, strong expression was detected in PDAC, which further increased 
in PDAC + OJ. To exclude that elevated MUC4 levels can be explained by the more advanced stages of PDAC + OJ 
patients, we compared MUC4 expressions both at the early and late stages of PC. Expression of MUC4 increased 
with the disease progression in the PDAC + OJ group, but not in the PDAC group, indicating that the elevated 
level of MUC4 is due to the specific action of BAs. We also found that the presence of biliary obstruction was 
related to poor survival of the PDAC + OJ patients. Several studies have revealed that overexpression of MUC4 
is associated with a poor clinical outcome and this gene has been reported to be an independent prognostic fac-
tor in  PC49–52. In order to clarify the role of MUC4 in the bile-induced cancer progression, we down-regulated 
MUC4 by siRNA transfection and found that MUC4 act as an oncogenic mucin. The oncogenic potential of 
MUC4 is not surprising since silencing of MUC4 decreases the proliferation of many cancer cells. Li et al. have 
shown that 96 h after the transfection with shRNA, lentivector for MUC4 decreased the cell growth of BxPC-3 
cells, both under in vitro and in vivo  conditions42. Similar results have been found in other pancreatic cancer cell 
 lines18,41,53,54. We have also demonstrated that inhibition of MUC4 expression significantly decreased the effect 
of TCDCA, one of the most effective BAs, indicating that the tumorigenic effect of bile is mediated by MUC4.
Figure 8 shows a hypothetic schematic figure regarding the role of BAs in PC progression. BAs induce cell 
death in normal pancreatic ductal cells; that are probably an anti-cancer, defensive mechanism. In contrast, 
elevated serum BAs levels increase MUC4 expression in PC, that presumably accelerates tumour progression. 
Figure 8.  Schematic diagram of the effect of bile acids. Bile acids (BAs) decrease the cell viability of normal 
pancreatic ductal cells and induce cell death in order to avoid malignant transformation. In the case of 
pancreatic ductal adenocarcinoma (PDAC) bile promotes the tumorigenic potential of the cancer cells in which 
the increased expression of MUC4 plays essential role.
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Based on these results, we believe that in PC patients with OJ, treatment of biliary obstruction needs to be done 
as early as possible to decrease the tumorigenic potential of PC cells and improve the life expectancy.
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